- Home
- ASMB vs SNAL Comparison
ASMB vs SNAL Comparison
Compare ASMB & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- SNAL
- Stock Information
- Founded
- ASMB 2005
- SNAL 2000
- Country
- ASMB United States
- SNAL United States
- Employees
- ASMB N/A
- SNAL N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- SNAL Computer Software: Prepackaged Software
- Sector
- ASMB Health Care
- SNAL Technology
- Exchange
- ASMB Nasdaq
- SNAL Nasdaq
- Market Cap
- ASMB 139.8M
- SNAL 51.0M
- IPO Year
- ASMB 2010
- SNAL 2022
- Fundamental
- Price
- ASMB $18.75
- SNAL $1.40
- Analyst Decision
- ASMB Strong Buy
- SNAL
- Analyst Count
- ASMB 3
- SNAL 0
- Target Price
- ASMB $33.00
- SNAL N/A
- AVG Volume (30 Days)
- ASMB 43.5K
- SNAL 83.0K
- Earning Date
- ASMB 08-07-2025
- SNAL 08-12-2025
- Dividend Yield
- ASMB N/A
- SNAL N/A
- EPS Growth
- ASMB N/A
- SNAL N/A
- EPS
- ASMB N/A
- SNAL 0.04
- Revenue
- ASMB $32,154,000.00
- SNAL $90,462,190.00
- Revenue This Year
- ASMB $0.04
- SNAL $24.50
- Revenue Next Year
- ASMB N/A
- SNAL $20.27
- P/E Ratio
- ASMB N/A
- SNAL $35.90
- Revenue Growth
- ASMB 148.33
- SNAL 46.95
- 52 Week Low
- ASMB $7.75
- SNAL $0.52
- 52 Week High
- ASMB $19.93
- SNAL $3.42
- Technical
- Relative Strength Index (RSI)
- ASMB 65.84
- SNAL 57.34
- Support Level
- ASMB $18.01
- SNAL $1.34
- Resistance Level
- ASMB $18.99
- SNAL $1.65
- Average True Range (ATR)
- ASMB 0.84
- SNAL 0.17
- MACD
- ASMB -0.05
- SNAL -0.00
- Stochastic Oscillator
- ASMB 84.42
- SNAL 36.21
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.